Improving Outcome Disparities for Latino Children and Adolescents with Acute Lymphoblastic Leukemia

改善患有急性淋巴细胞白血病的拉丁裔儿童和青少年的结果差异

基本信息

  • 批准号:
    10289493
  • 负责人:
  • 金额:
    $ 112.29万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-08-20 至 2024-07-31
  • 项目状态:
    已结题

项目摘要

Summary Acute lymphoblastic leukemia (ALL) is the most common cancer in children and, although cure rates have improved over the past 50 years, ethnic disparities persist. In particular, Latinos have the highest incidence and among the lowest survival rates for leukemia in the U.S. The underlying causes of this disparity are multi-factorial, including differences in tumor and host biology, as well as social/behavioral factors such as limited healthcare access. Host pharmacogenomics and other biological factors resulting in increased treatment-related toxicities are a key and under-studied cause of ethnic disparities in outcomes. Adverse outcomes result both from direct treatment-associated morbidity and mortality, and from compromised ability to deliver sufficiently intensive anti- leukemic therapy. The overall goals of this P20 program are to reduce outcome disparities among Latino children and adolescents by identifying host biological factors that result in increased toxicities, and to lay the groundwork for establishment of the first Specialized Programs of Research Excellence (SPORE) devoted to pediatric leukemia. The two primary Research Projects will identify factors associated with risk for two key treatment-related toxicities, hepatotoxicity and neurotoxicity, which adversely impact treatment outcomes and occur disproportionately in Latinos. The eventual SPORE will expand upon this work by (1) pursuing prevention and treatment strategies and (2) investigating ethnic disparities in other clinically impactful treatment-related toxicities. The Program will be administered through the Administrative Core (Core A). Biospecimens will be processed by Core B, and statistical analysis will be provided by Core C. A Developmental Research Program will foster development of innovative pilot projects that aim to understand and/or reduce ethnicity-based disparities in ALL outcomes. We will leverage the Reducing Ethnic Disparities in Acute Leukemia (REDIAL) Consortium, comprising 6 cancer centers in the southwestern U.S., which will provide clinical data from 3,000 and clinical data, bone marrow, blood and cerebrospinal fluid samples from nearly 2,000 children and adolescents with newly diagnosed ALL for the following two novel and integrated Projects. Our synergistically integrated team will define key biological factors associated with hepatotoxicity and neurotoxicity, important contributors to ethnic outcome disparities. More broadly, this Program will further strengthen and expand the REDIAL Consortium, with its invaluable ethnically diverse dataset and biorepository, and model its use for development of risk prediction models that identify Latino patients at risk for toxicities and illuminate the underlying biology mechanisms. This work will form the foundation for a future SPORE that will investigate additional toxicities of ALL therapy, and translate these findings into development of effective intervention strategies. This efficient monetary investment will result in significant reductions in outcome disparities in Latino children and adolescents with ALL.
总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Philip Lupo其他文献

Philip Lupo的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Philip Lupo', 18)}}的其他基金

Effects of germline GATA3 variants on ALL somatic genomics and prognosis in multi-ethnic populations
种系 GATA3 变异对多种族人群中 ALL 体细胞基因组学和预后的影响
  • 批准号:
    10390748
  • 财政年份:
    2022
  • 资助金额:
    $ 112.29万
  • 项目类别:
An Integrative Approach to Evaluate Neurocognitive Disparities in Latinos Undergoing Treatment for Childhood Leukemia.
评估接受儿童白血病治疗的拉丁裔神经认知差异的综合方法。
  • 批准号:
    10459987
  • 财政年份:
    2022
  • 资助金额:
    $ 112.29万
  • 项目类别:
Improving Outcome Disparities for Latino Children and Adolescents with Acute Lymphoblastic Leukemia
改善患有急性淋巴细胞白血病的拉丁裔儿童和青少年的结果差异
  • 批准号:
    10472696
  • 财政年份:
    2021
  • 资助金额:
    $ 112.29万
  • 项目类别:
Improving Outcome Disparities for Latino Children and Adolescents with Acute Lymphoblastic Leukemia
改善患有急性淋巴细胞白血病的拉丁裔儿童和青少年的结果差异
  • 批准号:
    10683983
  • 财政年份:
    2021
  • 资助金额:
    $ 112.29万
  • 项目类别:
Molecular epidemiology of acute lymphoblastic leukemia in children with Down syndrome
唐氏综合症儿童急性淋巴细胞白血病的分子流行病学
  • 批准号:
    10885331
  • 财政年份:
    2020
  • 资助金额:
    $ 112.29万
  • 项目类别:
Air Toxics, Neighborhood Environment and Risk of Oral Clefts
空气毒物、社区环境和唇裂风险
  • 批准号:
    8540860
  • 财政年份:
    2012
  • 资助金额:
    $ 112.29万
  • 项目类别:
Air Toxics, Neighborhood Environment and Risk of Oral Clefts
空气毒物、社区环境和唇裂风险
  • 批准号:
    8243869
  • 财政年份:
    2012
  • 资助金额:
    $ 112.29万
  • 项目类别:

相似海外基金

Understanding of the onset and recurrence pattern of intractable acute lymphocytic leukemia based on clone analysis
基于克隆分析了解难治性急性淋巴细胞白血病的发病和复发模式
  • 批准号:
    20K08723
  • 财政年份:
    2020
  • 资助金额:
    $ 112.29万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Novel Inhibitors of Multi-Drug-Resistant Mutants of BCR-ABL for the Treatment of Chronic Myelogenous Leukemia (CML) and Ph Positive Acute Lymphocytic Leukemia (ALL).
BCR-ABL 多重耐药突变体的新型抑制剂,用于治疗慢性粒细胞白血病 (CML) 和 Ph 阳性急性淋巴细胞白血病 (ALL)。
  • 批准号:
    9047400
  • 财政年份:
    2015
  • 资助金额:
    $ 112.29万
  • 项目类别:
The Role of Genetic Variants in Sensitivity to Methotrexate in Acute Lymphocytic Leukemia Survivors
遗传变异在急性淋巴细胞白血病幸存者对甲氨蝶呤敏感性中的作用
  • 批准号:
    319114
  • 财政年份:
    2014
  • 资助金额:
    $ 112.29万
  • 项目类别:
    Fellowship Programs
Targeting the Bone Marrow Microenvironment In Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的骨髓微环境
  • 批准号:
    8595788
  • 财政年份:
    2013
  • 资助金额:
    $ 112.29万
  • 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
  • 批准号:
    8023518
  • 财政年份:
    2011
  • 资助金额:
    $ 112.29万
  • 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
  • 批准号:
    8404025
  • 财政年份:
    2011
  • 资助金额:
    $ 112.29万
  • 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
  • 批准号:
    8220724
  • 财政年份:
    2011
  • 资助金额:
    $ 112.29万
  • 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
  • 批准号:
    8599754
  • 财政年份:
    2011
  • 资助金额:
    $ 112.29万
  • 项目类别:
INSULIN RESISTANCE IN CHILDREN WITH ACUTE LYMPHOCYTIC LEUKEMIA UNDERGOING INDUCT
正在接受治疗的急性淋巴细胞白血病儿童的胰岛素抵抗
  • 批准号:
    8356701
  • 财政年份:
    2010
  • 资助金额:
    $ 112.29万
  • 项目类别:
INSULIN RESISTANCE IN CHILDREN WITH ACUTE LYMPHOCYTIC LEUKEMIA UNDERGOING INDUCT
正在接受治疗的急性淋巴细胞白血病儿童的胰岛素抵抗
  • 批准号:
    8166720
  • 财政年份:
    2009
  • 资助金额:
    $ 112.29万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了